Profile data is unavailable for this security.
About the company
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
- Revenue in EUR (TTM)277.70m
- Net income in EUR39.05m
- Incorporated1997
- Employees1.14k
- LocationEckert & Ziegler SERobert-Roessle-Str.10BERLIN 13125GermanyDEU
- Phone+49 309410840
- Fax+49 30 941084112
- Websitehttps://www.ezag.com/
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 27 Sep 2024 | 608.20k | 2.87% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 507.97k | 2.40% |
| Janus Henderson Investors UK Ltd.as of 30 Sep 2024 | 440.65k | 2.08% |
| Groupama Asset Management SAas of 31 Oct 2024 | 326.94k | 1.54% |
| UBS Asset Management Switzerland AGas of 30 Sep 2024 | 231.92k | 1.10% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 213.34k | 1.01% |
| Amundi Asset Management SA (Investment Management)as of 06 Nov 2024 | 207.27k | 0.98% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 201.63k | 0.95% |
| Lupus alpha Asset Management AGas of 30 Jun 2024 | 178.00k | 0.84% |
| KBC Asset Management NVas of 30 Jun 2024 | 160.70k | 0.76% |
